Will Pfizer Head Higher After Recent Headlines?
T = Trends for a Stock’s Movement
Pfizer is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company manages its operations through five segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health and Consumer Healthcare, and Nutrition. Pfizer’s main products are human and animal biologic and small molecule medicines, as well as vaccines, nutritional products, consumer healthcare products, and products for the prevention and treatment of diseases in livestock and companion animals.
Pfizer’s experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study’s primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease. Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company’s most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body.”We are delighted with the final data,” Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration “to determine next steps” for palbociclib.